Tellgen

Tellgen Debt Growth

The Year-over-Year Debt Growth of Tellgen (300642.SZ) as of Oct 25, 2026 is 268.10 %. In the previous year, Year-over-Year Debt Growth was 1,512.97 % — a change of -82.28% (lower).

Debt Growth

268.10 %

YoY

-82.28%

Last updated:

Year-over-Year Debt Growth of Tellgen is 2025 268.10 % . Year-over-Year Debt Growth of Tellgen was 2024 1,512.97 % . It decreases by -82.28% lower compared to the previous year.

The Tellgen Debt Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt Growth
Date
Debt Growth
Jan 1, 2016
37.25 CNY
Jan 1, 2019
-33.82 CNY
Jan 1, 2020
-6.14 CNY
Jan 1, 2021
2.77 CNY
Jan 1, 2022
29.74 CNY
Jan 1, 2023
-72.53 CNY
Jan 1, 2024
1,512.97 CNY
Jan 1, 2025
268.10 CNY
The Tellgen Debt Growth history
YEARDebt GrowthYoY
268.10 %-82.28%
1,512.97 %-2,185.87%
-72.53 %-343.88%
29.74 %+972.67%
2.77 %-145.19%
-6.14 %-81.86%
-33.82 %-190.79%
37.25 %-435.29%
-11.11 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tellgen Stock analysis

What does Tellgen do? Tellgen Corp develops, manufactures, and markets molecular diagnostic products including immunodiagnostic, molecular diagnostic, and biochemical diagnostic products. Their portfolio features tumor marker detection, HPV nucleic acid testing, autoimmune disease detection, and lung cancer methylation mutation detection products. The company targets healthcare providers and laboratories seeking advanced diagnostic solutions for disease detection and monitoring. Tellgen Corp generates revenue through the sale of these specialized diagnostic products to medical institutions and healthcare facilities. The firm's product lines focus on specific diagnostic needs such as cancer screening and infectious disease testing. Immunodiagnostic products detect antibodies and antigens, molecular diagnostic products analyze genetic material, and biochemical diagnostic products measure metabolic markers. Tellgen Corp sells these products directly to hospitals, clinics, and diagnostic laboratories across China and potentially internationally. Tellgen Corp's revenue streams come from the commercialization of its diagnostic product portfolio. The company's offerings address key healthcare challenges including early cancer detection and infectious disease management. Their products are designed to support clinical decision-making and patient care pathways in medical settings. Tellgen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tellgen stock

Year-over-Year Debt Growth of Tellgen is 268.10 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Debt Growth Tellgen since 2006 – with annual values, charts, and detailed analysis.

Debt growth measures the percentage change in total debt. Rising debt growth should be compared with revenue and earnings growth to assess sustainability.

To evaluate Year-over-Year Debt Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Debt Growth.

Year-over-Year Debt Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Debt Growth's Tellgen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Tellgen

All Key Metrics — Tellgen